Reported about 19 hours ago
Amgen Inc. announced positive results from its Phase 3 FORTITUDE-101 trial for Bemarituzumab, demonstrating improved overall survival in patients with advanced gastric cancer with FGFR2b overexpression. This groundbreaking monoclonal antibody, targeting a specific protein, marks a significant advancement in treatment options for this serious condition, as gastric cancer remains a leading cause of cancer-related deaths globally. Further detailed results and additional trials are anticipated in the upcoming months.
Source: YAHOO